B
BeiGene Ltd
BGNE
162.540
USD
-4.19
(-2.51%)
مغلق
حجم التداول
1,899
الربح لكل سهم
0
العائد الربحي
0
P/E
-45
حجم السوق
23,380,295,136
الأخبار
العنوان: BeiGene Ltd
القطاع: Healthcare
الصناعة: Biotechnology
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.